Showing 171-180 of 263 results for "".
- New Study on AI-Driven Solutions for Diabetic Eye Disease Testing in Underserved Populations Publishedhttps://modernod.com/news/new-study-on-ai-driven-solutions-for-diabetic-eye-disease-testing-in-underserved-populations-published/2482441/Michael D. Abramoff, MD, PhD, founder and executive chairman of Digital Diagnostics, and the creator of the LumineticsCore AI system for diagnosing diabetic retinopathy, has co-authored a study exploring the potential of autono
- University of Toronto Researchers Build Online Glaucoma Simulatorhttps://modernod.com/news/university-of-toronto-researchers-build-online-glaucoma-simulator/2481843/Researchers at the University of Toronto have built an online simulator that is designed to give an improved visual representation of the deterioration caused by glaucoma. The simulator, built by Prof. Willy Wong and PhD candidat
- Researchers Identify Potential Cause of Keratoconushttps://modernod.com/news/researchers-identify-potential-cause-of-keratoconus/2481402/Researchers at the University of North Texas Health Science Center are the first to characterize extracellular vesicles (EVs) in the tears of patients with keratoconus, according to an National Eye Institute news release. Dimitrios Karamichos, PhD, executive director of the North
- Illinois Tech Researcher Awarded $2.5 Million Grant to Prevent Vision Loss in Diabetes Patientshttps://modernod.com/news/illinois-tech-researcher-awarded-2-5-million-grant-to-prevent-vision-loss-in-diabetes-patients/2479432/Illinois Institute of Technology Professor of Biomedical Engineering Jennifer Kang-Mieler, PhD. has received a second research project grant (R01) from the National Institutes of Health to study diabetic retinopathy.
- Kodiak Sciences Announces Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at AAOhttps://modernod.com/news/kodiak-sciences-announces-presentation-of-durability-data-from-clinical-development-program-of-ksi-301-in-wet-amd-dme-and-rvo-at-aao/2476945/Kodiak Sciences announced that Charles C. Wykoff, MD, PhD, will present first-time results at the annual mneeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco. The Retina Subspecialty Day (
- EyePoint Pharmaceuticals Names New Members of Executive Leadership Teamhttps://modernod.com/news/eyepoint-pharmaceuticals-names-new-members-of-executive-leadership-team/2476642/EyePoint Pharmaceuticals announced the appointment of Scott Jones as Chief Commercial Officer and Said Saim, PhD, as Chief Technology Officer. Mr. Jones will be responsible for the commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammatio
- Oculis Elects Anthony Rosenberg and David A. Weber to Its Board of Directorshttps://modernod.com/news/oculis-elects-anthony-rosenberg-and-david-a-weber-to-its-board-of-directors/2479867/Oculis announced the appointments of Anthony Rosenberg as Non-Executive Chairman and David A. Weber, PhD, as Non-Executive Director. Together, they bring more than 60 years’ experience from the global pharmaceutical and eye care industries to the compa
- CIRM Awards $4.7 Million for Vision Loss Gene Therapyhttps://modernod.com/news/cirm-awards-47-million-for-vision-loss-gene-therapy/2482827/The California Institute for Regenerative Medicine (CIRM) awarded $4.7 million to Blue Gen Therapeutics Foundation (Principal Investigator Aaron Nagiel, MD, PhD) to fund preclinical research that aims to develop a gene therapy for the rare disease blue cone monochromacy (BCM). <
- Rayner Completes Recruitment for RayOne Galaxy IDE Studyhttps://modernod.com/news/rayner-completes-recruitment-for-rayone-galaxy-ide-study/2482642/Rayner announced the closure of recruitment in the Investigational Device Exemption (IDE) study for the RayOne Galaxy IOL in the United States. Developed in collaboration with Brazilian ophthalmologist João Lyra, MD, PhD, RayOne Galaxy is the worl
- Outlook Therapeutics Presents Results from NORSE EIGHT Trial Evaluating ONS-5010 for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-presents-efficacy-and-safety-results-from-norse-eight-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd/2482632/Outlook Therapeutics announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting. Baruch D. Kuppermann, MD, PhD, of Gavin Herbert Eye Institute, University of California, Irvine, CA presented the abstract titled, “ONS-5010 (bevacizumab-vikg